Sai Life Sciences Limited reported a 22% year-on-year increase in consolidated net profit to ₹73 crore for the quarter ended June 30, 2026, driven by a 12% rise in revenue from operations to ₹554 crore. The Hyderabad-based Contract Research, Development and Manufacturing Organization (CRDMO) also saw its EBITDA grow 18% to ₹148 crore, with the margin expanding to 27% from 25% in the corresponding period last year. This performance underscores strong demand across its Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments, alongside disciplined cost management.

The Board of Directors, chaired by Managing Director Krishna Kanumuri, approved the unaudited financial results at a meeting held on August 6, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors M/s. Deloitte Haskins & Sells LLP. The filing was made pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An earnings call is scheduled for August 7, 2026, at 4:00 PM IST to discuss the financial and business performance.

Financial Performance

Consolidated revenue from operations reached ₹554 crore in Q1FY27, up from ₹496 crore in Q1FY26. Total income stood at ₹557.83 crore. Profit before tax increased 21% to ₹97.97 crore. Total tax expense for the group was ₹24.69 crore. Basic earnings per share (EPS) were ₹3.46 on a consolidated basis, up from ₹2.90 in Q1FY26.

On a standalone basis, revenue from operations grew 13% to ₹546.73 crore. Standalone net profit rose 22% to ₹71.34 million. Finance costs decreased significantly to ₹76.36 million on a consolidated basis from ₹123.64 million year-ago, contributing to the bottom-line improvement.

Operational Highlights

Managing Director Krishna Kanumuri highlighted a shift in client expectations toward integrated discovery and development programs. He noted that large pharmaceutical companies are increasingly engaging Sai for strategic partnerships due to its technology base and scientific talent. Chief Financial Officer Siva Chittor added that the CRO segment maintained strong momentum with 24% year-on-year growth. The CMC pipeline continues to strengthen with 33 active commercial molecules and 14 late-phase molecules. The company also reported encouraging traction in its Full-Time Equivalent (FTE)-led engagement model.

Operationally, Sai Life Sciences operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad, during the quarter. Additionally, the company achieved an EcoVadis Platinum Rating for sustainability, placing it in the top 1% of companies assessed worldwide. These developments support the company’s long-term growth strategy and capacity expansion plans.

What the Numbers Show

The expansion in EBITDA margin to 27% from 25% indicates improved operating leverage despite revenue growth being moderate at 12%. The significant reduction in finance costs, down nearly 40% year-on-year, played a crucial role in boosting net profit growth to 22%, outpacing revenue growth. The strong double-digit growth in the CRO segment suggests that high-value research services are driving profitability, while the robust pipeline of commercial and late-phase molecules provides visibility into future CDMO revenues. The achievement of the EcoVadis Platinum Rating further enhances the company’s appeal to global clients prioritizing sustainable supply chains.

Sai Life Sciences Limited has scheduled meetings with analysts and investors for August 13 and 14, 2026, in Singapore. The company will participate in the Avendus Spark INDX-Asia Edition 2026 event, engaging stakeholders through both one-on-one and group discussions to provide updates on its business operations and strategic direction.

The disclosure was made in compliance with Regulations 30 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015. The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 04, 2026, regarding the upcoming engagement schedule.

Meeting Details

The interactions are structured to allow detailed dialogue between the company’s management and market participants. The format includes both individual consultations and broader group sessions, facilitating comprehensive coverage of investor queries.

Regulatory Compliance and Disclosure Policy

Runa Karan, Company Secretary and Compliance Officer of Sai Life Sciences Limited, signed the intimation letter submitted to the exchanges. The filing explicitly states that the company does not intend to discuss any unpublished price-sensitive information (UPSI) during these meetings. Furthermore, no new presentation materials will be distributed or presented during the sessions.

The schedule is subject to change due to exigencies on the part of the analysts, investors, or the company. Investors are advised to monitor official communications for any updates regarding timing or format adjustments. The meetings aim to maintain transparency and regular communication with the investment community without disclosing material non-public information.